3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Pancreatic Neoplasms
4
Breast Neoplasms
3
Melanoma
2
Colorectal Neoplasms
2
Untreated Resectable Pancreatic Adenocarcinoma
1
Resectable Localized Prostate Cancer
1
Prostatic Neoplasms
1
Prostate Cancer Recurrent
1
Pancreatic Ductal Adenocarcinoma
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neoplasms
1
Neoplasm, Residual
1
Liver Neoplasms
1
Klatskin Tumor
1
Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
1
Glioma
1
Gastrointestinal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Adenocarcinoma
1
Interventions
Cyclophosphamide
12
fludarabine phosphate
7
fludarabine
7
venetoclax
6
blinatumomab
6
Cytarabine
5
Lenalidomide
4
Dexamethasone
4
Blood Specimen Collection
4
Azacitidine
4
obinutuzumab
3
Rituximab
3
Radiotherapy
3
Melphalan
3
Immunotherapy, Adoptive
3
pembrolizumab
2
daratumumab
2
Neoadjuvant Therapy
2
Idarubicin
2
Chemotherapy, Adjuvant
2
Capecitabine
2
trastuzumab deruxtecan
1
tislelizumab
1
tisagenlecleucel
1
thymoglobulin
1
tetrathiomolybdate
1
talquetamab
1
tagraxofusp
1
sacituzumab govitecan
1
sabatolimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm, Residual
×
Hydroxychloroquine
×
1 year
×
Clear all
NCT04841148
2026-04-09
PALAVY
Abramson Cancer Center at Penn Medicine
Phase 2
Recruiting
96 enrolled